Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q2 2021 · 10-Q
Revenue$416.00K$416.00K+20,700.0% vs Q2 2020 Net Income$4.41M$4.41MN/M vs Q2 2020 EPS Diluted-$0.01-$0.01N/M vs Q2 2020 Operating Income-$12,407,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-2982.5%+368817.5 pt vs Q2 2020
Net margin1060.1%+2898660.1 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 16, 2021 · 47 d after period end